Additionally, ZHX2 was reported to have tumor suppressor activity in hepatocellular carcinoma (HCC), by repressing cyclin A, E, and multidrug resistance 1 (MDR1) expression (Ma et al., 2015; Yue et al., 2012). Here, CCNA2 is linked to hepatocellular carcinoma.